These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33813074)

  • 1. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis.
    Koutoukidis DA; Jebb SA; Tomlinson JW; Cobbold JF; Aveyard P
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e538-e547. PubMed ID: 33813074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
    Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Lassailly G; Caiazzo R; Ntandja-Wandji LC; Gnemmi V; Baud G; Verkindt H; Ningarhari M; Louvet A; Leteurtre E; Raverdy V; Dharancy S; Pattou F; Mathurin P
    Gastroenterology; 2020 Oct; 159(4):1290-1301.e5. PubMed ID: 32553765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial.
    Sato M; Akamatsu M; Shima T; Ikegami T; Yanase M; Mikami S; Imamura J; Nakatsuka T; Tateishi R; Yamauchi N; Ushiku T; Okanoue T; Fujishiro M; Hida E; Koike K
    Am J Gastroenterol; 2023 Aug; 118(8):1365-1372. PubMed ID: 36656974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
    Pais R; Aron-Wisnewsky J; Bedossa P; Ponnaiah M; Oppert JM; Siksik JM; Genser L; Charlotte F; Thabut D; Clement K; Ratziu V
    Hepatology; 2022 Aug; 76(2):456-468. PubMed ID: 35076966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Nonalcoholic Steatohepatitis Be Surgically Cured?: Liver Histologic Comparison After Metabolic Surgery Versus Usual Care.
    Aminian A; Wilson R; Al-Kurd A; Bena J; Fayazzadeh H; Alkhouri N; Nissen SE; Dasarathy S
    Ann Surg; 2024 Feb; 279(2):276-282. PubMed ID: 37212393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.
    Vilar-Gomez E; Calzadilla-Bertot L; Friedman SL; Gra-Oramas B; Gonzalez-Fabian L; Lazo-Del Vallin S; Diago M; Adams LA
    Liver Int; 2017 Dec; 37(12):1887-1896. PubMed ID: 28544769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
    Musso G; Cassader M; Paschetta E; Gambino R
    JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.
    Pennisi G; Celsa C; Enea M; Vaccaro M; Di Marco V; Ciccioli C; Infantino G; La Mantia C; Parisi S; Vernuccio F; Craxì A; Cammà C; Petta S
    Nutr Metab Cardiovasc Dis; 2022 Oct; 32(10):2279-2288. PubMed ID: 35970684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
    Heath L; Aveyard P; Tomlinson JW; Cobbold JF; Koutoukidis DA
    Hepatol Commun; 2022 Oct; 6(10):2623-2633. PubMed ID: 35903833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
    J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.